These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 7644656)

  • 41. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
    Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
    Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Management of Graves' ophthalmopathy by using orbital magnetic resonance imaging].
    Hiromatsu Y; Eguchi H; Tani J
    Nihon Rinsho; 2012 Nov; 70(11):1932-7. PubMed ID: 23214064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Surgical treatment of diplopia in patients with Graves' ophthalmopathy].
    Luo Q; Li P; Tang L; Zhou X; Xia R
    Zhonghua Yan Ke Za Zhi; 2002 Aug; 38(8):470-1. PubMed ID: 12410984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy.
    Tachibana S; Murakami T; Noguchi H; Noguchi Y; Nakashima A; Ohyabu Y; Noguchi S
    Endocr J; 2010; 57(10):853-61. PubMed ID: 20733265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Value of MRI in the treatment of Grave's disease orbital myopathy].
    Oğuz V; Yolar M; Yetik H; Cakirer D; Uysal O; Pazarli H
    J Fr Ophtalmol; 2001 Oct; 24(8):842-6. PubMed ID: 11894535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Magnetic Resonance evaluation of disease activity in Graves' ophthalmopathy: T2-time and signal intensity of extraocular muscles.
    Majos A; Pajak M; Grzelak P; Stefańczyk L
    Med Sci Monit; 2007 May; 13 Suppl 1():44-8. PubMed ID: 17507884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Corticosteroids and radiotherapy in the treatment of Graves' ophthalmopathy].
    Nasr E; Khater S; Nehme-Nasr D; Azoury F; Jambart S
    J Med Liban; 2010; 58(2):86-90. PubMed ID: 20549894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of extraocular muscles in the edematous phase of Graves ophthalmopathy on contrast-enhanced fat-suppressed magnetic resonance imaging.
    Cakirer S; Cakirer D; Basak M; Durmaz S; Altuntas Y; Yigit U
    J Comput Assist Tomogr; 2004; 28(1):80-6. PubMed ID: 14716237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Extraocular muscle aspects of the treatment in dysthyroid ophthalmopathy].
    Baba H; Yoshikawa K; Mizuno T; Inoue T; Inoue Y
    Nippon Ganka Gakkai Zasshi; 1989 Jul; 93(7):785-9. PubMed ID: 2610156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-year recurrence rate of Graves ophthalmopathy presenting as diplopia in the primary position after varied doses of intravenous methylprednisolone followed by oral prednisolone with dosing based on the magnetic resonance imaging findings.
    Ueki S; Hasegawa Y; Hatase T; Kiyokawa M; Fukuchi T
    Jpn J Ophthalmol; 2023 Jan; 67(1):91-96. PubMed ID: 36301447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction.
    Day RM; Carroll FD
    Arch Ophthalmol; 1968 Mar; 79(3):279-82. PubMed ID: 5694289
    [No Abstract]   [Full Text] [Related]  

  • 52. Idiopathic isolated abscess in an extraocular muscle in a child.
    Haufschild T; Weber P; Nuttli I; Hecker B; Flammer J; Kaiser HJ
    Arch Ophthalmol; 2004 Aug; 122(8):1233-4. PubMed ID: 15302671
    [No Abstract]   [Full Text] [Related]  

  • 53. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
    Smith TJ; Janssen JAMJL
    Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Update on thyroid eye disease and management.
    Bothun ED; Scheurer RA; Harrison AR; Lee MS
    Clin Ophthalmol; 2009; 3():543-51. PubMed ID: 19898626
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves' orbitopathy.
    Johnson KT; Wittig A; Loesch C; Esser J; Sauerwein W; Eckstein AK
    Graefes Arch Clin Exp Ophthalmol; 2010 Jan; 248(1):103-9. PubMed ID: 19865824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Endocrine orbitopathy 1998].
    Förster G; Kahaly G
    Med Klin (Munich); 1998 Jun; 93(6):365-73. PubMed ID: 9662944
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Graves ophthalmopathy: MR evaluation of 10-Gy versus 24-Gy irradiation combined with systemic corticosteroids.
    Nakahara H; Noguchi S; Murakami N; Morita M; Tamaru M; Ohnishi T; Hoshi H; Jinnouchi S; Nagamachi S; Futami S
    Radiology; 1995 Sep; 196(3):857-62. PubMed ID: 7644656
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extraocular muscles in Graves ophthalmopathy: usefulness of T2 relaxation time measurements.
    Ohnishi T; Noguchi S; Murakami N; Tajiri J; Harao M; Kawamoto H; Hoshi H; Jinnouchi S; Futami S; Nagamachi S
    Radiology; 1994 Mar; 190(3):857-62. PubMed ID: 8115640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [MR relaxation time measurements with and without selective fat suppression (SPIR) in endocrine orbitopathy].
    Pauleit D; Schüller H; Textor J; Leutner C; Keller E; Sommer T; Träber F; Block W; Boldt I; Schild H
    Rofo; 1997 Dec; 167(6):557-64. PubMed ID: 9465949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.